These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 27312965)
1. Management of anaplastic lymphoma kinase positive orbito-conjunctival inflammatory myofibroblastic tumor with crizotinib. Kiratli H; Uzun S; Varan A; Akyüz C; Orhan D J AAPOS; 2016 Jun; 20(3):260-3. PubMed ID: 27312965 [TBL] [Abstract][Full Text] [Related]
2. Complete and Repeated Response of a Metastatic ALK-rearranged Inflammatory Myofibroblastic Tumor to Crizotinib in a Teenage Girl. Gaudichon J; Jeanne-Pasquier C; Deparis M; Veyssière A; Heyndrickx M; Minckes O; Orbach D J Pediatr Hematol Oncol; 2016 May; 38(4):308-11. PubMed ID: 26808369 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement. Rafee S; Elamin YY; Joyce E; Toner M; Flavin R; McDermott R; Sheehy N; Hennessy B; O'Byrne K; Gleeson N; Osman N Tumori; 2015 Apr; 101(2):e35-9. PubMed ID: 25744866 [TBL] [Abstract][Full Text] [Related]
4. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib. Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698 [TBL] [Abstract][Full Text] [Related]
5. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. Butrynski JE; D'Adamo DR; Hornick JL; Dal Cin P; Antonescu CR; Jhanwar SC; Ladanyi M; Capelletti M; Rodig SJ; Ramaiya N; Kwak EL; Clark JW; Wilner KD; Christensen JG; Jänne PA; Maki RG; Demetri GD; Shapiro GI N Engl J Med; 2010 Oct; 363(18):1727-33. PubMed ID: 20979472 [TBL] [Abstract][Full Text] [Related]
6. Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature. Liu Q; Kan Y; Zhao Y; He H; Kong L Int J Clin Exp Pathol; 2015; 8(11):15328-32. PubMed ID: 26823889 [TBL] [Abstract][Full Text] [Related]
7. More on crizotinib. Orenstein JM N Engl J Med; 2011 Feb; 364(8):777; author reply 778-9. PubMed ID: 21345112 [No Abstract] [Full Text] [Related]
8. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. Mossé YP; Voss SD; Lim MS; Rolland D; Minard CG; Fox E; Adamson P; Wilner K; Blaney SM; Weigel BJ J Clin Oncol; 2017 Oct; 35(28):3215-3221. PubMed ID: 28787259 [TBL] [Abstract][Full Text] [Related]
9. Crizotinib in ALK Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567 [TBL] [Abstract][Full Text] [Related]
10. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects. Brivio E; Zwaan CM Pediatr Blood Cancer; 2019 May; 66(5):e27645. PubMed ID: 30697903 [TBL] [Abstract][Full Text] [Related]
12. ALK negative inflammatory myofibroblastic tumor of the orbit: a masquerading entity. Dutta V; Manoj MG; Malik A; Kumar P Indian J Ophthalmol; 2014 May; 62(5):627-9. PubMed ID: 24881614 [TBL] [Abstract][Full Text] [Related]
13. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. Alan O; Kuzhan O; Koca S; Telli TA; Basoglu T; Ercelep O; Filinte D; Sengul Y; Arikan H; Kaya S; Babacan NA; Dane F; Yumuk PF J Oncol Pharm Pract; 2020 Jun; 26(4):1011-1018. PubMed ID: 31615346 [TBL] [Abstract][Full Text] [Related]
14. Inflammatory myofibroblastic tumor of the conjunctiva: response to chemotherapy with low-dose methotrexate and vinorelbine. Favini F; Resti AG; Collini P; Casanova M; Meazza C; Trecate G; Ferrari A Pediatr Blood Cancer; 2010 Mar; 54(3):483-5. PubMed ID: 19890966 [TBL] [Abstract][Full Text] [Related]
15. Infantile inflammatory myofibroblastic tumors: clinicopathological and molecular characterization of 12 cases. Lopez-Nunez O; John I; Panasiti RN; Ranganathan S; Santoro L; Grélaud D; Wu T; Buccoliero AM; Casanova M; Alaggio R; Surrey LF Mod Pathol; 2020 Apr; 33(4):576-590. PubMed ID: 31690781 [TBL] [Abstract][Full Text] [Related]
16. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer. Guo L; Zhang H; Shao W; Chen B Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259 [TBL] [Abstract][Full Text] [Related]
17. Anaplastic lymphoma kinase-negative pulmonary inflammatory myofibroblastic tumor with multiple metastases and its treatment by Apatinib: A case report. Liu Q; Wei J; Liu X; Wang J Medicine (Baltimore); 2019 Dec; 98(52):e18414. PubMed ID: 31876714 [TBL] [Abstract][Full Text] [Related]
18. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges. Mahajan P; Casanova M; Ferrari A; Fordham A; Trahair T; Venkatramani R Curr Probl Cancer; 2021 Aug; 45(4):100768. PubMed ID: 34244015 [TBL] [Abstract][Full Text] [Related]
19. Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report. Kothari S; Ud-Din N; Lisi M; Coyle T J Med Case Rep; 2016 Jun; 10():176. PubMed ID: 27301488 [TBL] [Abstract][Full Text] [Related]
20. Infratemporal inflammatory myofibroblastic tumour with orbital extension. Chow SP; Nastri A; Hardy T Clin Exp Ophthalmol; 2010 Oct; 38(7):727-30. PubMed ID: 20497435 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]